AMP-945 is under clinical development by Amplia Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AMP-945’s likelihood of approval (LoA) and phase transition for Idiopathic Pulmonary Fibrosis took place on 25 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 25 Nov 2021 increased AMP-945’s Phase Transition Success Rate (PTSR) for Pancreatic Ductal Adenocarcinoma, and increased PTSR for Squamous Cell Carcinoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AMP-945 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AMP-945 overview

AMP-945 (CTX-0294945) is under investigation for the treatment of idiopathic pulmonary fibrosis, pancreatic ductal adenocarcinoma, metastatic pancreatic cancer, fibrotic Interstitial Lung Diseases, non-alcoholic steatohepatitis (NASH) and squamous cell carcinoma. It is a small molecule administered through oral route. It acts by targeting focal adhesion kinase (FAK).

It was also under development for the treatment of triple negative breast cancer.

Amplia Therapeutics overview

Amplia Therapeutics, formerly Innate Therapeutics Ltd, is a pharmaceutical company. The company focuses on the development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. It lead drug candidate, AMP945, is a small molecule targeting focal adhesion kinase (FAK) in fibrotic tumors such as pancreatic and ovarian cancer; and the other drug candidate AMP886 is a multi-action molecule targeting VEGFR3 and FLT3 cancer pathways in solid and hematological cancers. As FAK is a significant target in cancer immunology, the company has focus on FAK inhibitors for treating cancers and chronic diseases such as idiopathic pulmonary fibrosis. Amplia Therapeutics is headquartered in North Melbourne, Victoria, Australia.

Quick View AMP-945 LOA Data

Report Segments
  • Innovator
Drug Name
  • AMP-945
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.